Jaguar Health 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Jaguar Health reported total net revenue for prescription products of approximately $500,000 in the 3rd quarter of 2026, primarily from Mytesi supplied to FuturePak at cost-plus terms, compared with approximately $1.2 million in the 2nd quarter of 2026 and approximately $3 million in the 3rd quarter of 2025.
- Jaguar’s loss from operations narrowed to $6 million in the 3rd quarter of 2026 from $7.2 million in the 3rd quarter of 2025, while net loss narrowed to $5.8 million from $9.6 million.
- Non-GAAP recurring EBITDA was a net loss of approximately $5 million in the 3rd quarter of 2026, compared with a net loss of $9 million in the 3rd quarter of 2025.
- Jaguar said it reduced its outstanding debt balance by over $10 million in the 3rd quarter of 2026.
- Jaguar received an approximately $1.8 million non-dilutive holdback payment from FuturePak in August 2026 and recognized $42,000 in 3rd-quarter license fees from a European partner; deferred revenue associated with that contract was $425,000 as of September 30th, 2026.
- The company reported compassionate-use results in which parenteral support requirements normalized to body weight fell by up to 48% in an MVID patient and by up to 40% in 2 short bowel syndrome IF pediatric patients after more than a year of crofelemer treatment, with no safety issues reported.
- NeoNorm Dog became available from Amazon; Jaguar said it expects availability through other animal health channels.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning. Before I turn the call over to management, I would like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, product initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information and management's current assumptions, expectations, and projections of future events. While management believes its assumptions, expectations, and projections are reasonable in the view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements.
The company's actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and risk factor section of the company's 10-K form for the year 2025, which was filed with the SEC on April 7th, 2026. Its other filings with the SEC, which are available on the investor relations section of Jaguar's website. Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events, or otherwise. Additionally, please note that the company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP Recurring EBITDA. Jaguar believes that the disclosure items on these non-GAAP measures provide investors with additional information that reflects the basis upon which the company's management assesses and operates the business.
These non-GAAP financial measures should not be viewed in isolation or as substitutes for GAAP net sales, GAAP net loss, and are not substitutes for or superior to measures of financial performance in conformity with GAAP. Today's conference is being recorded. At this time, it is my pleasure to turn the call over to Lisa Conte, Jaguar Health's founder, president, and chief executive officer. Lisa, the floor is yours.
Thank you, Sherry. Thank you, everybody, for joining the investor webcast today. As you heard, my name is Lisa Conte. I am the founder, president, and CEO of Jaguar Health and our wholly owned subsidiary, Napo Pharmaceuticals. I am also the chairman of our Italian subsidiary, Napo Therapeutics. As usual, I may use the words Jaguar and Napo interchangeably when I am referring to the company. After I speak today, our CFO, Carol Lizak, will provide a recap of the financial highlights for the third quarter of 2026. One key highlight that I want to highlight, Jaguar significantly reduced its outstanding debt balance by over $10 million in the third quarter of 2026. Once again, the theme of today's webcast is transformational near-term catalysts and sharp strategic focus.
If you have followed the company in the past, you may recall that in January of 2026, we completed what we consider a transformative transaction, the signing of a U.S. commercial out-license agreement with Future Pak for Mytesi, the brand name of our FDA-approved formulation of crofelemer for adults living with HIV/AIDS and diarrhea. Included in that license also was Canalevia-CA1, our conditionally FDA-approved formulation of crofelemer for doggies with chemotherapy-induced diarrhea. We made this strategic decision to out-license Mytesi to Future Pak first because they had recently acquired Theratechnologies, an HIV-focused commercial company with more than four times the commercial effort of Jaguar in the United States. The HIV space, and they're focused completely in the U.S. HIV space, and they have other HIV-related products.
Secondly, this fulfilled our strategic plan to bring in meaningful non-dilutive dollars to help fund our sharp development focus on our late-stage clinical development program for a novel proprietary powder for oral solution formulation of crofelemer. Significance of the novel formulation is that this is a different product, a whole different business structure of crofelemer, specifically for rare intestinal failure indications. Same active ingredient, same product, certain manufacturing activities are common to Mytesi, yet a different formulation for the rare intestinal failure indications. Rare, meaning we have orphan drug designation for the intestinal failure indications, two different indications in both the United States and Europe.
While Jaguar, Napo, remains the manufacturer of Mytesi and Canalevia-CA1, therefore supplying the product to Future Pak at a cost-plus term, so a profit center there, we are now fully a rare disease GI company with 100% of our human development efforts sharply and strategically focused on this rare disease program. For many years prior to the out-license agreement with Future Pak, we were selling Mytesi ultimately into the distributors and had a sales force promoting directly to the physicians who were prescribing Mytesi to patients, and the expense associated with that, and the expense associated with a single product as opposed to the Theratech situation right now.
At this point, we are operating as a supplier of Mytesi to Future Pak, and therefore a much different impact on the reporting of sales and the revenue numbers that we are reporting, but a different impact on the non-dilutive dollars that we receive from that agreement. Back to our main strategic focus. Our ultimate strategy continues to involve evaluating strategic alternatives driven by the tremendous value to potential development and a commercialization partner for our rare disease intestinal failure program, for our late-stage rare disease intestinal failure program. Just to put this in perspective, the out-license to Future Pak was $18 million upfront, primarily for the U.S. HIV market, a market with a peak annual market opportunity of maybe $50 million-$70 million annually.
The global market for short bowel syndrome, which includes our bowel syndrome with intestinal failure, as well as some rare congenital disorders, is estimated to reach more than $8 billion in 2033, according to third-party market research. A different third-party market research estimates the value of just the global MVID marketplace, which is an ultra-rare indication for which there are no treatments, nothing in clinical development. They put that estimate at over $2 billion by 2032. Again, our strategic goal is to again bring in non-dilutive dollars from a strategic partner, as we did with Future Pak for Mytesi. Market differences are in the tens of millions for Mytesi for HIV U.S. versus billions for intestinal failure globally. I just referred to MVID. It's pediatric microvillus inclusion disease, as I mentioned, an ultra-rare disorder, no approved therapies, a lethal natural history.
This is Jaguar's very near-term value driver in the intestinal failure program. It's our lead target indication. We have completed enrollment in a pivotal trial, a blinded pivotal trial to support a targeted new drug application submission in mid-2027. We're talking like eight, nine, 10 months away. This is very exciting, meaningful to MVID patients, and the catastrophic impact to their health, and to the impact on their family and other supportive caregivers, of which there are many for MVID patients. As awareness in crofelemer's impact grows with respect to our compassionate use patients, which has been published and presented at various medical conferences, we've experienced many patient and physician inquiries for future possibility for access to crofelemer.
Short bowel syndrome, which you'll hear me refer to as SBS or SBS-IF, short bowel syndrome with intestinal failure, represents a larger follow-on indication using the same dosage formulation and the same physiological mechanism for intestinal failure as with MVID patients. SBS and MVID are both separate rare disease orphan designations, each in the U.S. and Europe. Our intestinal failure program represents a blockbuster global market opportunity, first and foremost in terms of addressing the catastrophic unmet medical need in patients, blockbuster in terms of the beneficial impact to morbidity and mortality, and the cost to the healthcare system, and then also the financial return opportunity for all stakeholders, including our shareholders. This return opportunity, of course, is especially important to the motivation and the incentive to potential corporate partners and strategic alternatives that we are looking at.
As I mentioned, the global market for SBS-IF is estimated at over $8 billion, again by a third party in 2033, MVID over $2 billion. I want to take a moment to describe not just dollars, but the catastrophic impact of intestinal failure on patients and what this means for their caregiving community, which includes family members, healthcare professionals, nurses, nutritionists, others. It does take a village to manage these situations. Intestinal failure, it's a debilitating condition that often requires patients to receive life-sustaining fluids, electrolytes, IV administration for the nutrients of life, which is all encompassed in something called TPN, total parenteral nutrition. Total parenteral nutrition with supplemental fluids is called parenteral support. This is IV nutritional support, IV nutritional support. Many intestinal failure patients require this parenteral support up to 20 hours a day, seven days a week. IV nutrition. So obviously, this is a catastrophic situation for the patient, both from a healthcare standpoint and the obvious impact on quality of life.
Parenteral support is supportive, it is necessary for life, it is sustenance, yet it is associated with quite serious complications, including liver and kidney toxicities, compromised cognitive functioning, negative impact on growth, infections, line infections from being on IV nutrition, and ultimately, not just the morbidity aspects of all that, but mortality as well. This is why standard of care parenteral support, TPN, is referred to as lethal natural history for these patients. And the cost is meaningful. It is estimated at about $500,000 a year in the United States per patient, and the cost to the healthcare system is inevitably higher, can top $1 million per year per patient due to the complications of infections and keeping that balance of nutrients of life correct.
And this is all on top of the mortality risk. MVID is a congenital disease, so the patient, the infant, the baby, is born and has massive diarrhea and is unable to absorb nutrients of life. If the baby is not diagnosed immediately, the newborn, they often die right away. If the newborn is diagnosed, they will be on parenteral support for the rest of their life. Again, up to seven days a week, 20 hours a day. The key of what we are looking for in providing adjunctive therapy to these patients is a reduction in the amount of time they are on parenteral support. Parenteral support is life-sustaining, but can we reduce the amount of time that they are on parenteral support and therefore have a significant impact on the massive toxicities and comorbidities that are life-shortening for these patients, and in this case, for these infants?
Even a reduction of 5%-10% is considered clinically meaningful. Remember, these are infants, enabling the baby to grow to a child and thrive is life and disease altering and altering for the family condition as well. So, the endpoint in the crofelemer clinical development program is, in fact, the reduction in parenteral support. Let us say even 10%-15%. That would allow the patient to receive a significant percentage of their parenteral support at night while sleeping, preserving some quality of life, the ability to go to school during waking hours. The patient would not need to be attached to an IV to go through some of their normal activities of daily living, and that, of course, reduces the situation and the environment and the circumstances for infection as well.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
